ClinicalTrials.gg
Not yet recruitingNCT07368283Updated Jan 30, 2026

Limited Target Volume Radiotherapy After Glioblastoma Surgery

An interventional study of limited-field radiotherapy in Glioblastoma (GBM), sponsored by Jiangxi Provincial Cancer Hospital. Not yet recruiting. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-01-30.

Sponsored by Jiangxi Provincial Cancer Hospital · Not applicable, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
79
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Study summary

Research on radiotherapy target volumes for glioblastoma is increasingly focused on exploring more limited yet effective irradiation fields, aiming to achieve local control while minimizing acute and long-term neurotoxicity. Previous retrospective analysis by investigators revealed that local recurrences of glioblastoma are predominantly confined to a narrow margin around the original lesion: 98.3% of recurrences occurred within 0.5 cm of the original T2-FLAIR abnormality, 94.8% within 1 cm of the original T1-enhanced region. These findings have been cited in the ESTRO-EANO treatment guidelines. Building on this evidence, investigators plan to conduct a single-arm, phase II clinical trial to systematically evaluate the efficacy and safety of a 1 cm radiotherapy target volume in post-operative glioblastoma patients.Eligible patients with glioblastoma who have undergone surgical resection will be selected to receive limited-field radiotherapy. The target volume will be defined based on the postoperative MRI enhancing lesion: a 1 cm margin will be added to form the clinical target volume (CTV), followed by a further 0.3 cm margin to create the planning target volume (PTV). A total dose of 60 Gy will be delivered in 30 fractions (2 Gy per fraction, 5 fractions per week). Concurrent and adjuvant chemotherapy will be administered per standard guidelines. The primary efficacy endpoints are the 6-month progression-free survival rate and the incidence of symptomatic radiation-induced brain necrosis of grade 3 or higher. Secondary endpoints include overall survival, patterns of recurrence, neurocognitive function, and quality of life.

02

Conditions studied

  • Glioblastoma (GBM)

Browse trials for

03

In context

Glioblastoma

2,137 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

This study's planned enrollment of 79 is above the median of 36 across 1,758 interventional studies indexed under Glioblastoma.

Browse Glioblastoma studies →

Lead sponsor

Jiangxi Provincial Cancer Hospital is the lead sponsor of 34 studies on the registry; 19 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged between 18 and 70 years.
  • Diagnosed with glioblastoma by surgical pathology, with the extent of resection achieving maximal safe resection.
  • Within 2 to 6 weeks after surgery
  • In good physical condition with a Performance Status (KPS) score ≥ 60.
  • Hematological, hepatic, and renal functions are essentially normal.
  • Signed , willing to undergo treatment and follow-up as stipulated in the study protocol.

Exclusion criteria

Exclusion Criteria:

  • Prior history of cranial radiotherapy or other malignant tumors.
  • Severe dysfunction of vital organs (e.g., heart, liver, kidneys) that precludes tolerance to radiotherapy.
  • Active infection, immune system disorders, or other serious chronic diseases.
  • Pregnancy or lactation.
  • Psychiatric disorders or severe cognitive impairment that compromises the ability to cooperate with treatment and follow-up.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
79 participants (estimated)

Study arms

  • Other
    limited-field radiotherapy Group

    Radiation: limited-field radiotherapy

Interventions

  • Radiationlimited-field radiotherapy

    limited-field radiotherapy + Concurrent and adjuvant TMZ chemotherapy

06

What researchers measure

Primary outcomes

  1. 6m PFS

    6-month progression-free survival rate

    Time frame: up to 6 month

  2. incidence of symptomatic radiation-induced brain necrosis of grade 3 or higher

    Time frame: Up to 24 months

Secondary outcomes

  1. OS

    overall survival

    Time frame: Up to 24 months

  2. Location of first recurrence relative to radiation field (in-field, marginal, or distant)

    The spatial relationship between the first documented site of disease recurrence/progression and the original radiation treatment plan will be determined by a core imaging laboratory. Recurrent lesions will be co-registered with the original planning CT/MRI and radiation dose distribution. Classification is based on the volume of the recurrent lesion covered by the 95% isodose line of the original prescription dose: In-field recurrence: \>80% of the recurrent lesion's volume is within the 95% isodose line. Marginal recurrence: 20% to 80% of the recurrent lesion's volume is within the 95% isodose line. Distant recurrence: \<20% of the recurrent lesion's volume is within the 95% isodose line. This classification criteria is adapted from the dosimetric analysis methods commonly used in radiotherapy studies (e.g., Patterns offailure for glioblastoma multiforme following limited-margin radiation and concurrent temozolomide. Radiation oncology 2014, 9:130.)

    Time frame: Up to 24 months

  3. Cognitive function assessed by Mini-Mental State Examination (MMSE) score

    Cognitive function assessed by the Mini-Mental State Examination (MMSE). Scores range from 0 to 30, with higher scores indicating better cognitive function.

    Time frame: Up to 24 months

  4. Cognitive function assessed by Montreal Cognitive Assessment (MoCA) score

    Cognitive function assessed by the Montreal Cognitive Assessment (MoCA). Scores range from 0 to 30, with higher scores indicating better cognitive function.

    Time frame: Up to 24 months.

  5. Health-Related Quality of Life as assessed by the EORTC QLQ-C30 Global Health Status / QoL scale

    Score on the Global Health Status / Quality of Life scale (Items 29 \& 30) of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). Scale range: 0-100. A higher score indicates a better overall quality of life.

    Time frame: Up to 24 months

  6. Disease-Specific Quality of Life as assessed by the EORTC QLQ-BN20 summary score

    Summary score of the European Organization for Research and Treatment of Cancer Brain Cancer Module (EORTC QLQ-BN20). This scale assesses symptoms and issues specific to brain tumor patients (e.g., future uncertainty, visual disorder, motor dysfunction). Scale range and interpretation should be specified

    Time frame: Up to 24 months

  7. Quality of Life as assessed by the FACT-Br Total Score

    Total score of the Functional Assessment of Cancer Therapy - Brain (FACT-Br). This questionnaire assesses physical, social, emotional, functional well-being, and additional concerns specific to brain tumor patients. Scale range: 0-200. A higher score indicates better quality of life.

    Time frame: Up to 24 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2026; primary completion for Dec 2028, 35 months later.

Of 133 non-industry interventional studies with no phase under Glioblastoma, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 97. This study's planned 35 months is below that.

Counting every sponsor, half of 151 studies reached it within 54 months; a quarter within 36 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2026
First posted
Jan 26, 2026
StartEst.
Jan 2026
Primary completionEst.
Dec 2028
CompletionEst.
Dec 2030
Last update
Jan 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07368283
Lead sponsor
Jiangxi Provincial Cancer Hospital
Responsible party
Zhiping Chen (Director of the Head and Neck Radiation Therapy Department,Jiangxi cancer Hospital, Jiangxi Provincial Cancer Hospital) — Principal investigator
First posted
Jan 26, 2026
Start date
Jan 2026 (estimated)
Primary completion
Dec 2028 (estimated)
Completion
Dec 2030 (estimated)
Last update
Jan 30, 2026

Study contacts

Ziwei Tu
Contact
tuziwei198803@163.com
13755793552

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion